TARGETED DELIVERY OF CHEMOTHERAPEUTIC DRUGS TO EPHA2-EXPRESSING CANCER CELLS
SUMMARY
Targeted drug delivery systems (TDDS) has been used to overcome obstacles facing cancer chemotherapy which includes toxicity, side effects and lack of tumor selectivity. TDDS for cancer takes advantage of the growing number of tumor specific cell surface molecular biomarkers to design targeted delivery modules. EphA2 receptor tyrosine kinase is one of the therapeutic target for cancer. Antibody-drug conjugate (ADC) and peptide-drug conjugate (PDC) has been exploited to deliver cytotoxic drug to EphA2 expressing cells. This paper therefore describes both conjugates, its pros and cons and recommends the best alternative.
BACKGROUND
Cancer, the leading causes of morbidity and mortality worldwide currently has chemotherapy, radiation therapy and surgery as treatment options [1, 2]. Radiation therapy and surgery are termed localized therapies because they are focused on getting rid of or stopping growth of tumors that are limited to localized areas [3]. Chemotherapy on the other hand plays a significant role in cancer treatment as it prevents not only local growth of tumor cell and tissues but also provides systemic treatment for metastases.
Currently, cancer chemotherapy relies heavily on indiscriminate, nonspecific systemic biodistrubution and highly toxic
…show more content…
This overview will describe nanotechnological approaches that has been used to develop novel targeted drug delivery systems to EphA2 expressing cancer cells. It will focus on some EphA2 targeted polymeric drug conjugates (antibody and peptide drug conjugates) and suggest the best solution in my opinion among